Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - AMERICAN BIO MEDICA CORP | abmc_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): April 15,
2021
AMERICAN BIO MEDICA CORPORATION
(Exact name of registrant as specified in its charter)
New
York
|
0-28666
|
14-1702188
|
(State or other
jurisdiction of incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification Number)
|
122
Smith Road, Kinderhook, NY
|
12106
|
(Address of
principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: 518-758-8158
Not applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see
General Instruction A.2.
below):
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each
class
|
Trading
Symbol(s)
|
Name of each
exchange on which registered
|
Common
|
ABMC
|
OTC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
ITEM
2.02 RESULTS OF OPERATIONS AND
FINANCIAL CONDITION
On
April 15, 2021 American Bio Medica Corporation (the "Company")
announced financial results for the quarter and year ended December
31, 2020. A copy of the press release announcing the
Company’s results (the "Press Release") is attached hereto as
Exhibit 99.1 and is incorporated by reference in this Item 2.02.
The Press Release is available on the Company’s website. The
information provided in Item 2.02 of this report, including
Exhibit 99.1, shall be deemed to be “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended.
The
Company also expects to file its Form 10-K on April 15,
2020.
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AMERICAN BIO MEDICA
CORPORATION (Registrant)
|
|
|
|
|
|
|
Date:
April 15, 2021
|
By:
|
/s/ Melissa A.
Waterhouse
|
|
|
|
Melissa A. Waterhouse |
|
|
|
Chief Executive
Officer (Principal Executive Officer)
Principal Financial
Officer Title
|
|